The range and specificity of the humoral immune response to HIV-1 subtypes B and E was investigated in Thai samples. Sera from HIV-1-positive subjects, consisting of subtypes B (n = 24) and E (n = 138), were characterized in relation to the neutralization of primary isolates and T-cell line-adapted (TCLA) strains and binding to monomeric gp120, the CD4/gp120 binding site (BS), and V3 peptides. A subtype-specific pattern of antibody binding was observed with the exception of the CD4/gp 120MN BS. Neutralization of TCLA strains (n = 4) was strongly type-specific (p = .002); however, neutralization of primary isolates (n = 8) was weak and group specific. Thus, the subtype specificity of B and E sera in the neutralization of TCLA strains, but not primary isolates, supports the dominance of the V3 region in TCLA virus neutralization but does not support the distinction of subtypes B and E as discrete neutralization serotypes in Thailand.
The range and specificity of the humoral immune response to HIV-1 subtypes B and E were investigated in sera and plasma collected from 168 infected patients from Thailand in 1990-94. Specifically, samples were examined for the presence of binding antibody to env regions within monomeric gp120, the CD4/gp120 binding site, and the V3 domain as well as neutralizing antibodies to T-cell line-adapted (TCLA) and primary HIV-1 isolates from subtypes B and E. A subtype-specific pattern of antibody binding was observed with the exception of the CD4/gp120MN binding site. Although neutralization of TCLA strains was highly type-specific, neutralization of primary isolates was weak and group-specific. This finding supports the dominance of the V3 region in TCLA virus neutralization but fails to confirm the distinction of subtypes B and E as discrete neutralization serotypes in Thailand.
No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong
Qilu Normal University · Genelibs Bioinformatics Lab
750 Shunhua Rd, Jinan
2F, Bldg F, University Science Park
Tel: 0531-88819269
Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.
Business Email
E-mail: [email protected]